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This multi-national, double-blind, randomized, parallel-group study compared the efficacy and tolerability of 
fluticasone propionate 500yg twice daily propelled either by the non-chlorofluorocarbon (CFC) propellant, 
hydrofiuoroalkane (HFA) 134a, or the CFC propellants 11 and 12 used in the established pressurized metered ose 
inhaler (pMDI). The study period was 12 months and involved 412 subjects with moderate to severe asthma (HFA 
134a pMDI: n =203; CFC pMDI: n = 209). For the first 3 months, subjects kept a daily record card and attended 
the clinic every 4 weeks. Thereafter, they kept daily diaries for 2 weeks before each clinic assessment, which were 
performed at the end of 6, 9 and 12 months. 
Mean morning peak expiratory flow (PEF) increased uring the first week in both treatment groups. By the end 
of week 12 the adjusted mean increase from baseline in morning PEF was 21 and 23 1 min - I  in the HFA 134a and 
CFC pMDI groups, respectively, and this increase was maintained throughout the 12-month study period. Similar 
improvements were detected in other diary card parameters and in clinic lung function measurements. The two 
groups were shown to be clinically equivalent in terms of all efficacy variables and there were no differences in 
tolerability. There were few reports of low serum cortisol levels during the 12-month study period, and serum 
cortisol evels were similar at baseline and after 12 weeks and 12 months of treatment in the two groups. 
In conclusion, the new HFA 134a fluticasone propionate pMDI is as effective and safe as the established CFC 
fluticasone propionate pMDI when used at a dosage of I mg day-1. 
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Introduction 
First introduced in 1956, pressurized metered ose inhalers 
(pMDIs) are now the most commonly prescribed medical 
devices for the delivery of asthma medications in aerosol 
formulation. The fluticasone propionate pMDI remains a 
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popular device among experienced asthma patients and it is 
therefore important hat the availability of this product 
continues during the transition away from the chlorofluor- 
ocarbon (CFC) propellants, traditionally used in pMDIs to 
the approved non-ozone depleting propellant, hydrofluor- 
oalkane (HFA) 134a. 
Fluticasone propionate 500/~g twice daily improves lung 
function and symptom control in patients with asthma nd 
is well tolerated (1.-4). Furthermore, at this dosage, 
fluticasone propionate is at least as effective as twice the 
microgram dose of beclomethasone dipropionate in pa- 
tients with severe asthma (3). The objective of the present 
study was to compare the efficacy and tolerability of 
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fluticasone propionate 500 lag twice daily administered via a 
250,ug pMDI propelled by either the non-CFC propellant 
HFA 134a or the CFC propellants I1 and 12. Both 
formulations were assessed in patients with moderate to 
severe asthma over a period of 12 months. 
Methods 
SUBJECTS 
All subjects were aged >16 years and had a documented 
history of asthma which required and responded to 
treatment with inhaled corticosteroids (beclomethasone 
dipropionate 1 to 2 mg day -~ or equivalent, but not 
fluticasone propionate) and fla-agonist therapy. All patients 
were able to use a pMDI correctly, and their forced 
expiratory volume in 1 sec (FEV0 was 50 to 90 % of the 
predicted normal value. The inhaler technique of each 
patient was visually checked at the start of the study and 
corrected where necessary. 
To ensure that the study was able to demonstrate clinical 
equivalence, subjects had to show 'room for improvement' 
(5.). This was defined as a demonstrable mean morning peak 
expiratory flow (PEF) during the 2-week 'run-in' period of 
<90% of the PEF measured after inhalation of salbutamol 
400 or 800#g. If the response was insufficient after 
salbutamol 400 t,g, the 800 #g dose was used. Patients were 
also required to have used a symptomatic rescue bronch- 
odilator on at least four occasions during the last 7 days of 
the run-in period. 
Exclusion criteria included a change in regular asthma 
medication or respiratory tract infection requiring anti- 
biotics during the previous 4 weeks; concurrent use of 
inhaled fluticasone propionate; use of oral or parenteral 
corticosteroids on two or more occasions in the previous 4
months; and use of depot corticosteroids in the previous 3 
months. Also excluded were current or previous heavy 
smokers, pregnant or lactating women, or women not 
taking adequate contraceptive precautions. 
The study was approved by the appropriate local ethics 
committee and all subjects provided written informed 
consent. The study was performed in accordance with the 
principles of the Declaration of Helsinki and Good Clinical 
Practice. 
STUDY DESIGN 
This was a 12-month multi-national study with a double- 
blind, randomized, parallel-group design. Following a 2- 
week run-in period, patients entered an initial 12-week 
treatment period and were then offered the opportunity to 
continue in the study for an additional 9 months. Eligible 
subjects were randomized to treatment with fluticasone 
propionate 500 #g twice daily delivered by a fluticasone 
propionate 250 #g pMDI propelled by either HFA 134a or 
the CFC propellants 11 and 12. Standard pMDIs were 
used, and a large volume spacer device CV'olumatic TM) was 
provided based on individual patient requirement. 
PROCEDURE 
At the initial screening visit (prior to the run-in period), 
investigators performed a physical examination of the 
subjects and compiled a full medical history. Patients were 
given a CFC pMDI containing salbutamol to use as 
necessary for symptomatic relief. Any other short-acting 
fl2-agonists or inhaled corticosteroids (other than the study 
drug) were discontinued. All other asthma medication was 
continued at a constant dosage. 
Subjects received a mini-Wright peak flow meter and 
were asked to record details of morning and evening PEF, 
asthma symptoms and use of additional bronchodilator n 
a daily record card. Symptoms related to daily activities 
were measured on a six-point scale (0=no symptoms; 
5=symptoms so severe that the patients is unable to 
perform normal daily activities) and symptoms during the 
night were rated on a five-point scale (0= no symptoms; 
4 = symptoms so severe that the patient is unable to sleep at 
all). The record cards were completed aily during the first 
3 months of the study and daily thereafter during the 
2 weeks prior to each clinic visit. 
CL IN IC  VISITS 
Clinic visits were held every 4 weeks during the first 3 
months and at the end of 6, 9 and 12 months, with an 
additional foilow-up visit 2 weeks after study completion. 
Lung function (FEVI and PEF) was measured at each clinic 
visit. The equipment used to measure lung function was 
calibrated at regular intervals. At the end of the run-in 
period, and after 3, 6, 9 and 12 months, patients and 
physicians were asked to rate treatment efficacy as one of 
the following: very effective, effective, satisfactory, ineffec- 
tive or very ineffective, scored as 1 to 5, respectively. 
SAFETY  
Physical examinations, including measurement of pulse rate 
and blood pressure, were performed at the initial screening 
visit, and after 12 weeks and 12 months of treatment. 
Adverse vents were recorded at every visit. Blood samples 
were collected at 3-month intervals (between 08"00 and 
10-00 hours where possible) for routine haematological and 
biochemical analysis and measurement of serum cortisol 
levels. The analyses were performed by an appropriate 
central laboratory in each participating cou.ntry and 
abnormal findings were referred for further investigation. 
An oropharyngeal assessment was performed at each clinic 
visit during treatment to test for the presence of oral 
candidiasis. 
STAT IST ICAL  ANALYS IS  
The primary efficacy measure was mean morning PEF, 
derived from daily record card data. Equivalence was 
established if the 90% confidence interval (CI) for the 
treatment difference in mean morning PEF was within +__ 15 
I min-I  (6). Assuming a standard deviation of 30 to 
401 min- I  as observed in previous tudies, 125 evaluable 
subjects per treatment group were required to ensure a 
power of 80% (7). 
All analyses were performed on the intent-to-treat 
population. The change from baseline in mean morning 
and evening PEF, clinic visit FEVI and PEF, were analysed 
using analysis of covariance (ANCOVA) with baseline, age, 
centre and sex as the covariates and treatment as the main 
effect. The mean value recorded uring the last week of the 
run-in period was taken as the baseline value. Following 
logarithmic transformation, serum cortisol data were also 
analysed using ANCOVA. 
The Wilcoxon rank sum test, stratified by centre using 
the van Elteren extension (8), was used to establish any 
differences between treatment groups for symptom scores, 
use of additional bronchodilator medication and patient 
and physician assessment of efficacy. 
Resu l ts  
PATIENT CHARACTERISTICS 
Of the 412 patients randomized to treatment, 203 received 
fluticasone propionate HFA 134a pMDIs and 209 received 
TABLE I. Patient characteristics 
FLUTICASONE PROPIONATE 1 MG DAY-' VIA HFA 134a pMDI $37 
CFC pMDIs. The treatment groups were well matched for 
age, history of smoking, atopy and asthma, but were less 
well matched for gender (Table 1). A total of 75 subjects 
were withdrawn from the study, 35 from the HFA 134a 
pMDI group and 40 from the CFC pMDI group. The main 
reasons for withdrawal were adverse events (14 and 19 
patients in the HFA 134a and CFC pMDI groups, 
respectively), failure to return (nine and seven patients) 
and undefined reasons (10 and 11 patients). Three hundred 
and seventy patients progressed to the long-term (9-month) 
treatment period, 184 patients in the HFA 134a pMDI 
group and 186 in the CFC pMDI group. 
DAILY RECORD CARD DATA 
Similar improvements in mean morning PEF were reported 
in the two treatment groups after 1 week, and this trend 
continued throughout he 12-month study period despite 
the apparent differences in baseline PEF values between the 
two groups. After 12 weeks of treatment, he adjusted mean 
increase in morning PEF from baseline was 21 and 23 1 
min-  i respectively, in the HFA 134a (baseline 375 1 min- i )  
and CFC pMDI groups (baseline 3581min - I )  (Fig. 1). 
After 12 months, the corresponding improvements were 29 
Fluticasone propionate 
HFA 134a pMDI 
(n = 203) 
Fluticasone propionate 
CFC pMDI 
(n -- 209) 
Sex (no. of patients) 
Male 105 (52%) 
Female 98 (48%) 
Mean age (years; range) 46 (17-73) 
History of smoking (no. of patients) 
Never 118 (58%) 
Ex-smoker 69 (34%) 
Current 16 (8%) 
Use of spacer (no. of patients) 
Yes 147 (72%) 
No 56 (28%) 
Asthma medication continued into study 
(no. of patients): 
Long-acting/~2-agonists 65 (32%) 
Sodium cromoglycate 3 (1%) 
Nedocromil sodium 5 (2%) 
Methylxanthines 23 (11%) 
Anti-cholinergics 1 (< %) 
Duration of asthma (no. of patients): 
0-10 years 98 (48%) 
11-20 years 47 (23%) 
21-30 years 29 (14%) 
> 30 years 29 (14%) 
91 (44%) 
118 (56%) 
48 (19-75) 
123 (59%) 
72 (34°/,) 
14 (7%) 
161 (77%) 
48 (23%) 
61 (29%) 
4 (2%) 
2 (<1%) 
26 (12%) 
• 1 (< l%) 
102 (49%) 
50 (24%) 
22 (11%) 
35 (17%) 
CFC, chlorofluorocarbon; HFA, hydrofluoroalkane; pMDI, pressurized metered ose inhaler. 
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Fro. 1. Improvement in mean morning peak expiratory flow (PEF) over 12 weeks during treatment with fluticasone 
propionate I mg day-I administered via a chlorofluorocarbon (CFC) pressurized metered ose inhaler (pMDI) or a non- 
CFC (HFA 134a) pMDI. 
and 28 1 min-1, respectively. Statistical analysis confirmed 
that the two formulations of fluticasone propionate were 
within the predefined + 15 1 min- l  criterion set for clinical 
equivalence (90% CI for treatment difference: - 7, 41 min- l
at 12 weeks and -9 ,  10 1 min - l  at 12 months). 
Similar improvements in mean evening PEF were also 
reported. At 12 weeks the adjusted mean increase in 
evening PEF from baseline was 16 1 min - l  (baseline 391 I 
min -1) and 15 1 min - l  (baseline 378 I min - I )  in the HFA 
134a and CFC pMDI groups, respectively (90% CI for 
treatment difference:-5, 51min-t). At 12 months the 
corresponding increases were 21 and 19 1 min - l  (90% CI 
for treatment difference:-6, 11 I min-~). 
When expressed as a percentage of predicted normal 
values, changes in PEF from baseline were consistent with 
the morning and evening PEF results. After 12 weeks of 
therapy, mean increases from baseline in mean percent 
predicted morning PEF were 4 and 5% in the HFA 134a 
and CFC pMDI groups, respectively. By the end of 12 
months, mean morning PEF in both groups had increased 
by 6% from baseline. Changes from baseline in mean 
percent predicted evening PEF were 3% for both treatment 
groups at 12 weeks, and 5 and 4%, respectively, in the HFA 
134a and CFC pMDI groups at 12 months. 
Patients in both treatment groups reported fewer 
symptoms during the day or night than during the run-in 
period. At baseline, both groups had a median daytime 
symptom score of 1 (symptoms for one short period during 
the day); this decreased to 0 (no symptoms) in both groups 
by week 12 and remained at this level throughout the 
treatment period. Throughout he study, both treatment 
groups had a median ight-time symptom score of 0. The 
median percentage of symptom-free nights improved in 
both groups from a baseline of 71% to 100% at 12 weeks, 
where it remained until the end of the 12-month treatment 
period. Use of additional rescue bronchodilator was also 
low in both treatment groups (median of 0 puffs per day 
and night for most of the study). 
None of the diary card parameters in either treatment 
group indicated any difference in effect for subjects using a 
large volume (Volumatic TM) spacer device. ., 
CL IN IC  VISIT DATA 
There were no significant differences between treatments in
the mean change from baseline in clinic FEVI or PEF 
(Table 2). Mean FEVI values measured over the 12 months 
are shown in Fig. 2. 
Both the physicians' and subjects' assessment of efficacy 
remained constant throughout he 12-month study; a 
median score of 2 (effective) was recorded for both groups 
at 12 weeks and 12 months. 
SAFETY 
A similar number of subjects in both treatment groups 
reported adverse vents (Table 3) and the incidence of drug- 
related adverse vents was comparable in the two groups 
(51 and 58 patients in the HFA 134a and CFC pMDI 
groups, respectively). Serious adverse events (defined as 
fatal or life-threatening) were reported in 11 and 15 
patients, respectively, in the HFA 134a and CFC pMDI 
groups. Three and two serious adverse vents, respectively, 
in the HFA 134a and CFC pMDI groups were considered 
to be possibly related to the study drug. Fourteen patients 
TABLE 2. Clinic visit data 
FLUTICASONE PROPIONATE 1 MG DAY- '  VIA HFA 134a  pMDI $39 
Fluticasone Fluticasone Treatment 
propionate propionate difference 
HFA 134a CFC pMDI (SE) 
pMDI 
90%CI P-value 
FEVI (1) 
baseline (SD) 2"24 (0.70) 2"51 (0-68) 
Adjusted* mean change from baseline (SE) 
12 weeks 0.21 (0.03) 0-16 (0"03) 0.05 (0.04) --0.02, 0-12 0.216 
12 months 0-! 8 (0.03) 0.11 (0.03) 0-07 (0.04) 0.00, 0" 14 0" 104 
PEF (lmin - I )  
baseline (SD) 394 (93) 385 (104) 
Adjusted* mean change from baseline (SE) 
12 weeks 28 (4) 27 (4) 1 (6) --9, 10 0.927 
12 months 27 (5) 26 (5) 1 (6) -9 ,  12 0"820 
*Adjusted for baseline, age, centre and sex. 
CFC, chlorofluorocarbon; CI, confidence interval; FEVI forced expiratory volume in I sec; 
HFA, hydrofluoroalkane; pMDI, pressurized metered ose inhaler; PEF, peak expiratory flow; SD, 
standard eviation; SE, standard error. 
(7%) and 19 patients (9%), respectively, in the HFA 134a 
and CFC pMDI groups withdrew from the study due to an 
adverse vent. The most frequent adverse vents and the 
incidence of predictable adverse events associated with 
inhaled corticosteriod therapy are presented in Table 3. The 
use of a spacer device did not have a significant effect on the 
incidence of adverse vents. 
Mean serum cortisol concentrations remained similar to 
baseline levels throughout he study period, indicating a 
minimal effect of treatment on cortisol levels (Table 4). 
There was no evidence that either study treatment affected 
laboratory data or vital signs. 
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FIG. 2. Clinic visit forced expiratory volume in 1 sec 
(FEV0 during 12 months of treatment with fluticasone 
propionate 1mg day-  1 administered via a 
chlorofluorocarbon (CFC) pressurized metered ose 
inhaler (pMDI) (0 )  or a non-CFC (HFA 134a) 
pMDI (O). 
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Discussion 
The purpose of this study was to compare the efficacy and 
tolerability of fluticasone propionate 1mg day-1 adminis- 
tered by a 250 #g pMDI propelled either by the CFC 
propellants 11 and 12, or by the non-CFC propellent, HFA 
134a. The results demonstrate that over the 12-month 
treatment period, both formulations of fiuticasone propio- 
nate produced improvements in lung function and symp- 
toms as assessed by the patients and the investigators at 
clinic visits. Mean morning PEF increased within I week of 
the initiation of treatment in both groups and this 
improvement was maintained throughout he 12-month 
treatment period. These results are consistent with previous 
data on the onset of action of the HFA 134a pMDI product 
(9). These clinical data are also consistent with pharma- 
ceutical and pharmacokinetic data for the HFA 134a 
pMDI (10,11)Z 
In order to be able to establish true clinical equivalence, 
all patients were required to demonstrate 'room for 
improvement' during the run-in phase of the study. 
Notably, the 90% CI for the treatment difference in 
morning PEF remained well within the _+ 15 1 min -~ 
predefined equivalence criterion. Additional subsequent 
comparison of the maximum achievable PEF recorded in 
response to salbutamol 400 or 800#g'and the mean 
morning PEF recorded uring the study indicated that at 
12 weeks, more than 91% of patients had not achieved 95% 
of their maximum PEF value. At the end of 12 months, 
approximately 80% of patients had not achieved 95% of 
their maximum value. Therefore, comparisons between the 
two treatments were made on the curve and not on the 
plateau of the dose-response curve. Based on these data, it 
has been shown that both formations of fluticasone 
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TABLE 3. Most common and predictable adverse vents.durir~g treatment 
Fluticasone propionate 
HFA 134a pMDI 
(n = 203) 
Fluticasone propionate 
CFC pMDI 
(n = 209) 
Number of patients reporting an adverse vent 166 (82%) 
Most common adverse vents*: 
Upper respiratory tract infection 61 (30%) 
Asthma and related events 59 (29%) 
Headache 38 09%) 
Influenza 25 02%) 
Respiratory infection 20 (10%) 
Hoarseness 20 (10%) 
Rhinitis 20 (10%) 
Cough 14 (7%) 
Predictable adverse vents: 
Hoarseness 20 (10%) 
Candidiasis 11 (5%) 
Rash/skin eruption 6 (3%) 
Allergic skin reactions 2 (< 1%) 
163 (78%) 
58 (28%) 
56 (27%) 
39 (19%) 
20 (1o%) 
22 (11%) 
18 (9%) 
12 (6%) 
23 (11%) 
18 (9%) 
13 (6%) 
1 (<1%)  
l (< 1%) 
*Reported in >5% of patients. 
CFC, chlorofluorocarbon; HFA, hydrofluoroalkane; pMDI, pressurized metered ose inhaler. 
TABLE 4. Mean serum cortisol evels (nmol I- l) 
Fluticasone propionate Fluticasone propionate 90% CI 
HFA 134a pMDI CFC pMDI 
P-value 
Baseline (range) 355 (33-1240) 338 (50-944) 
12 weeks (range) 352 (65-985) 337 (8-1143) 
Adjusted* geometric ratio* 1-0 (n = 177)* 0.9 (n = 184) ;t 1.01, 1.22 
12 months (range) 358 (14-1164) 353 (10-1032) 
Adjusted* geometric ratio* 0"96 (n = 158)* 0"96 (n = 161)* 0" 89, 1-12 
0.07 
0.929 
*Adjusted for baseline, age, centre and sex. 
*Data at clinic visit divided by data at baseline. 
~;Subjects with data at baseline and from that visit. 
CFC, chlorofluorocarbon; CI, confidence interval; HFA, hydrofluoroalkane; pMDI, pressurized metered ose inhaler. 
propionate administered ata dosage of 1 mg day- i were of 
equivalent efficacy. These results are consistent with data 
from the clinical studies forming part of the development 
programme for the fluticasone propionate 125 and 250 #g 
HFA 134a pMDIs (9,12). 
The improvements in morning PEF were greater than 
expected given that all the patients had been taking 1-2 mg 
day -~ of inhaled corticosteroid prior to entry into the 
study. However, the increase in morning PEF was 
similar to that recorded in other studies using the same 
dose of fiuticasone propionate (2,13). Similar improvements 
in other diary card assessments, including mean evening 
PEF, symptom scores and use of rescue medication, were 
also reported in both treatment groups. Likewise, patients 
in both groups recorded similar increases in clinic PEF 
and FEVv 
Both formulations of fluticasone propionate were well 
tolerated, with similar rates of adverse vents. However, the 
incidence of hoarseness, candidiasis and cough was towards 
the upper end of values reported in previous studies of 
fluticasone propionate--typical incidences of hoarseness 
range from 0 to 11% and up to 7% for cough and 
candidiasis (14). The somewhat higher incidence may be 
attributable to the relatively high dose of fluticasone 
propionate used in this study, or perhaps patients requiring 
Volumatic TM spacers failed to use them for every dose. 
Nevertheless, reported events were not unexpected in the 
subject population being studied, the majority being 
associated with the underlying disease itself, and were 
similar to those reported in previous studies (1,2). The 
incidence of asthma and related adverse events was 
relatively high in both treatment groups (29 and 27*/0 in 
the HFA 134a and CFC pMDI groups) but reflects the 
method of reporting in this trial which involved actively 
questioning patients about adverse vents. There were no 
reports in either treatment group of paradoxical broncho- 
spasm which is a predictable adverse vent associated with 
the use of pressurized inhalers (15). 
In addition, there were very few reports of low serum 
cortisols throughout he 12-month study period; mean 
serum cortisol evels in both treatment groups were similar 
at baseline, and after 12 weeks and 12 months of treatment. 
These results are consistent with the findings of Fabbri et al. 
(16) who showed that serum cortisol evels did not decrease 
after 12 months of treatment with fluticasone propionate 
1.5 mg day-i .  
International asthma management guidelines recom- 
mend early intervention with inhaled corticosteroids 
(17,18). These agents are, therefore, widely prescribed. 
The pMDI still remains the most widely prescribed evice. 
It is therefore ncouraging that the results of our study, in 
common with others, show that fluticasone propionate at a 
dosage of I mg day- i propelled by the non-CFC propellant 
HFA 134 and administered via a pMDI, is a safe and 
effective long-term treatment for patients with moderate to 
severe asthma. 
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